GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Commercial partnership targets scalability, 24/7 PET imaging product access, and future expansion for next-gen cancer diagnostics.
Already a subscriber? Log in